Compare OSBC & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | JANX |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 984.3M |
| IPO Year | 2014 | 2021 |
| Metric | OSBC | JANX |
|---|---|---|
| Price | $24.04 | $15.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | $23.50 | ★ $47.00 |
| AVG Volume (30 Days) | 442.4K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $25.20 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $48.98 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.43 | $12.12 |
| 52 Week High | $23.99 | $35.34 |
| Indicator | OSBC | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 48.06 |
| Support Level | $19.21 | $13.13 |
| Resistance Level | N/A | $15.49 |
| Average True Range (ATR) | 0.45 | 0.61 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 89.44 | 4.80 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.